Stephen L. Hoffman
35Patents
10h-index
53Co-inventors
78Inventor score
Filing activity: May 16, 1988 → Dec 7, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5028588A | Blood substitutes | Chemistry; Metallurgy | 126 | Expired |
| US6455509B1 | Dengue nucleic acid vaccines that induce neutralizing antibodies | Emerging Cross-Sectional Technologies | 28 | Expired |
| US8043625B2 | Purified plasmodium and vaccine compositions | Emerging Cross-Sectional Technologies | 19 | Active |
| US7229627B2 | Apparatuses and methods for the production of haematophagous organisms and parasites suitable for vaccine production | Emerging Cross-Sectional Technologies | 18 | Expired |
| US8367810B2 | Purified plasmodium and vaccine compositions | Emerging Cross-Sectional Technologies | 17 | Active |
| US8992944B2 | Purified Plasmodium and vaccine composition | Emerging Cross-Sectional Technologies | 13 | Active |
| US5814617A | Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene | Emerging Cross-Sectional Technologies | 12 | Expired |
| US8802919B2 | Apparatuses and methods for the production of haematophagous organisms and parasites suitable for vaccine production | Emerging Cross-Sectional Technologies | 11 | Active |
| US9241982B2 | Purified plasmodium and vaccine compositions | Emerging Cross-Sectional Technologies | 11 | Active |
| US8821896B2 | Purified Plasmodium and vaccine composition | Emerging Cross-Sectional Technologies | 11 | Active |
| US9278125B2 | Pharmaceutical compositions comprising attenuated Plasmodium sporozoites and glycolipid adjuvants | Emerging Cross-Sectional Technologies | 7 | Active |
| US9616115B2 | Purified plasmodium and vaccine compositions | Emerging Cross-Sectional Technologies | 6 | Active |
| US9878026B2 | Infectious plasmodium sporozoites grown in vitro | Emerging Cross-Sectional Technologies | 5 | Active |
| US9642909B2 | Pharmaceutical compositions comprising attenuated Plasmodium sporozoites and glycolipid adjuvants | Emerging Cross-Sectional Technologies | 4 | Active |
| US7749519B2 | Unique DNA and polypeptide sequences based on the circumsporozoite protein of Plasmodium vivax | Emerging Cross-Sectional Technologies | 4 | Active |
| US10441646B2 | Infectious plasmodium sporozoites grown in vitro | Emerging Cross-Sectional Technologies | 3 | Active |
| US10272146B2 | Purified plasmodium and vaccine compositions | Emerging Cross-Sectional Technologies | 3 | Active |
| US5095093A | Protective four amino acid epitope against Plasmodium vivax malaria | Emerging Cross-Sectional Technologies | 2 | Expired |
| US8232255B2 | Methods for vaccinating against malaria | Emerging Cross-Sectional Technologies | 2 | Expired |
| US6066623A | Polynucleotide vaccine protective against malaria, methods of protection and vector for delivering polynucleotide vaccines | Emerging Cross-Sectional Technologies | 2 | Expired |
| US5198535A | Protective malaria sporozoite surface protein immunogen and gene | Emerging Cross-Sectional Technologies | 2 | Expired |
| US10695415B2 | Live attenuated oral vaccine against shigellosis and typhoid fever | Emerging Cross-Sectional Technologies | 1 | Active |
| US11503819B2 | Apparatus and method of use for an automated mosquito salivary gland extraction device | Emerging Cross-Sectional Technologies | 1 | Active |
| US5599543A | Immunogenic four amino acid epitope against Plasmodium vivax | Emerging Cross-Sectional Technologies | 1 | Expired |
| US6399062B1 | Murine monoclonal antibody protective against Plasmodium vivax malaria | Emerging Cross-Sectional Technologies | 1 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.